Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$635.83
-4.31-0.67%
At close: -
$635.83
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Regeneron Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:REGN | Benzinga
Regeneron Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Regeneron Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
Leerink Partners
Citigroup
Piper Sandler
UBS
1calculated from analyst ratings
Analyst Ratings for Regeneron Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/05/2025 | Buy Now | — | Baird | Brian Skorney57% | $940 → $759 | Maintains | Neutral | Get Alert |
| 02/05/2025 | Buy Now | — | Leerink Partners | David Risinger73% | $762 → $834 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/28/2025 | Buy Now | — | Citigroup | Geoff Meacham64% | $795 → $750 | Maintains | Neutral | Get Alert |
| 01/27/2025 | Buy Now | — | Piper Sandler | Christopher Raymond57% | $1195 → $1013 | Maintains | Overweight | Get Alert |
| 01/16/2025 | Buy Now | — | UBS | Trung Huynh69% | $1130 → $738 | Downgrade | Buy → Neutral | Get Alert |
| 01/14/2025 | Buy Now | — | Citigroup | Geoff Meacham64% | $895 → $795 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $1050 → $900 | Maintains | Overweight | Get Alert |
| 01/08/2025 | Buy Now | — | Truist Securities | Srikripa Devarakonda48% | $1126 → $1004 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | — | Bernstein | William Pickering45% | $1110 → $1070 | Maintains | Outperform | Get Alert |
| 12/17/2024 | Buy Now | — | Canaccord Genuity | John Newman45% | → $165 | Initiates | → Hold | Get Alert |
| 12/10/2024 | Buy Now | — | B of A Securities | Tim Anderson55% | → $565 | Reinstates | → Underperform | Get Alert |
| 11/15/2024 | Buy Now | — | Wolfe Research | Alexandria Hammond42% | → $1150 | Initiates | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | — | Citigroup | Geoff Meacham64% | → $895 | Initiates | → Neutral | Get Alert |
| 11/06/2024 | Buy Now | — | Oppenheimer | Hartaj Singh47% | $1150 → $1000 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | — | Morgan Stanley | Matthew Harrison60% | $1235 → $1184 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1260 → $1215 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | — | Barclays | Carter Gould58% | $1080 → $1065 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | — | Piper Sandler | Christopher Raymond57% | $1242 → $1195 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | — | BMO Capital | Evan David Seigerman53% | $1300 → $1190 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda48% | $1137 → $1126 | Maintains | Buy | Get Alert |
| 10/25/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1260 → $1260 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov70% | $1250 → $1175 | Maintains | Outperform | Get Alert |
| 10/24/2024 | Buy Now | — | JP Morgan | Chris Schott60% | $1200 → $1150 | Maintains | Overweight | Get Alert |
| 10/23/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 10/23/2024 | Buy Now | — | Barclays | Carter Gould58% | $1220 → $1080 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $1200 → $1050 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1260 → $1260 | Reiterates | Outperform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda48% | $1200 → $1137 | Maintains | Buy | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1252 → $1260 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1282 → $1252 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | — | BMO Capital | Evan David Seigerman53% | $1300 → $1300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/24/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda48% | $1200 → $1200 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | — | Leerink Partners | David Risinger73% | $1175 → $1077 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/23/2024 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $1200 → $1200 | Reiterates | Overweight → Overweight | Get Alert |
| 09/17/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1282 → $1282 | Reiterates | Outperform → Outperform | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 09/09/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1250 → $1282 | Maintains | Outperform | Get Alert |
| 09/05/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1250 → $1250 | Reiterates | Outperform → Outperform | Get Alert |
| 08/23/2024 | Buy Now | — | Piper Sandler | Christopher Raymond57% | $1166 → $1242 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | JP Morgan | Chris Schott60% | $1150 → $1200 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1232 → $1240 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | — | Guggenheim | Yatin Suneja49% | $1180 → $1300 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $1125 → $1200 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | Barclays | Carter Gould58% | $1200 → $1220 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda48% | $1135 → $1200 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | — | TD Cowen | Tyler Van Buren48% | $1030 → $1200 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $925 → $1000 | Maintains | Neutral | Get Alert |
| 07/19/2024 | Buy Now | — | Piper Sandler | Christopher Raymond57% | $1000 → $1166 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | — | Guggenheim | Yatin Suneja49% | $1040 → $1180 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | — | Morgan Stanley | Matthew Harrison60% | $1183 → $1182 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | — | Barclays | Carter Gould58% | $1050 → $1200 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | — | Canaccord Genuity | John Newman45% | $1152 → $1152 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | — | Argus Research | Jasper Hellweg69% | $1060 → $1170 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1229 → $1229 | Reiterates | Outperform → Outperform | Get Alert |
| 06/17/2024 | Buy Now | — | JP Morgan | Chris Schott60% | $1050 → $1150 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1200 → $1229 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1185 → $1200 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov70% | → $1150 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $925 → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/24/2024 | Buy Now | — | TD Cowen | Tyler Van Buren48% | $1020 → $1030 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | — | UBS | Colin Bristow41% | $1090 → $1099 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/15/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | $925 → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/12/2024 | Buy Now | — | B of A Securities | Geoff Meacham64% | $710 → $720 | Maintains | Underperform | Get Alert |
| 04/09/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1189 → $1189 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | — | Morgan Stanley | Matthew Harrison60% | $1104 → $1115 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | — | Bernstein | William Pickering45% | → $1125 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | Buy Now | — | Bernstein | Aaron Gal54% | → $1125 | Initiates | → Outperform | Get Alert |
| 02/27/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1096 → $1184 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $850 → $925 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1076 → $1110 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | — | BMO Capital | Evan David Seigerman53% | $1055 → $1082 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $1076 → $1076 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | — | Barclays | Carter Gould58% | $935 → $1020 | Maintains | Overweight | Get Alert |
| 01/12/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | → $1076 | Upgrade | Sector Perform → Outperform | Get Alert |
| 01/09/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer62% | $850 → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/18/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2023 | Buy Now | — | TD Cowen | Tyler Van Buren48% | $900 → $1000 | Maintains | Outperform | Get Alert |
| 11/29/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/28/2023 | Buy Now | — | Jefferies | Akash Tewari45% | $935 → $937 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | — | Deutsche Bank | James Shin42% | → $800 | Initiates | → Hold | Get Alert |
| 11/03/2023 | Buy Now | — | Piper Sandler | Christopher Raymond57% | $885 → $895 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $847 → $837 | Maintains | Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | — | Morgan Stanley | Matthew Harrison60% | $915 → $914 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | — | Raymond James | Dane Leone45% | → $950 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/16/2023 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | $800 → $850 | Maintains | Neutral | Get Alert |
| 10/12/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $833 → $847 | Maintains | Sector Perform | Get Alert |
| 10/11/2023 | Buy Now | — | Morgan Stanley | Matthew Harrison60% | $912 → $915 | Maintains | Overweight | Get Alert |
| 09/21/2023 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | → $800 | Reiterates | Neutral → Neutral | Get Alert |
| 09/15/2023 | Buy Now | — | Argus Research | Jasper Hellweg69% | $825 → $920 | Maintains | Buy | Get Alert |
| 09/15/2023 | Buy Now | — | WestPark Capital | — | — | Initiates | → Hold | Get Alert |
| 08/21/2023 | Buy Now | — | Canaccord Genuity | John Newman45% | $720 → $992 | Upgrade | Hold → Buy | Get Alert |
| 08/21/2023 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $875 → $980 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | — | Oppenheimer | Hartaj Singh47% | $950 → $1050 | Maintains | Outperform | Get Alert |
| 08/21/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $820 → $830 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Regeneron Pharmaceuticals (REGN) stock?
The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Baird on February 5, 2025. The analyst firm set a price target for $759.00 expecting REGN to rise to within 12 months (a possible 19.37% upside). 67 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by Baird, and Regeneron Pharmaceuticals maintained their neutral rating.
When was the last upgrade for Regeneron Pharmaceuticals (REGN)?
The last upgrade for Regeneron Pharmaceuticals Inc happened on February 5, 2025 when Leerink Partners raised their price target to $834. Leerink Partners previously had a market perform for Regeneron Pharmaceuticals Inc.
When was the last downgrade for Regeneron Pharmaceuticals (REGN)?
The last downgrade for Regeneron Pharmaceuticals Inc happened on January 16, 2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on February 5, 2025 so you should expect the next rating to be made available sometime around February 5, 2026.
Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a maintained with a price target of $940.00 to $759.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $635.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.